http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
-
Karyopharm Names New Head of Investor Relations
-
Karyopharm to Participate at the Barclays Global Healthcare Conference
-
Karyopharm Therapeutics (KPTI) receives FDA feedback that the current SIENDO study top-line results are unlikely to support an sNDA approval
-
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Therapeutics (KPTI) CMO has stepped down to pursue other professional opportunities
-
Karyopharm Announces Changes to Its Clinical Leadership Team
-
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
-
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Phase 3 SIENDO Study Meets Primary Endpoint
-
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
-
Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Therapeutics (KPTI) Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
-
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
-
Karyopharm to Present at B. Riley Securities Oncology Investor Conference
-
Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer
-
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
-
Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
-
Karyopharm Therapeutics (KPTI) Announces Collaboration with Ivy Brain Tumor Center to Develop Tissue-Based Clinical Trial for Brain Cancer
-
Ivy Brain Tumor Center and Karyopharm Therapeutics Collaborate to Develop Tissue-Based Clinical Trial for Brain Cancer
-
Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance
-
Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance
-
Biogen (BIIB) to Acquire Karyopharm Therapeutics (KPTI) KPT-350 for $10M and Up to $207M Additional
-
Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions
-
Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions
-
Medidata (MDSO) Expands Partnership with Karyopharm Therapeutics (KPTI) to Bring Machine Learning to Clinical Oncology Trials
-
Karyopharm and Medidata Expand Clinical Trial Partnership
-
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to Ring The Nasdaq Stock Market Closing Bell
-
Notable Analyst Rating Changes 8/18: (PCLN) (KMI) (TOO) Upgraded; (TWTR) (HMSY) (MMP) Downgraded
-
Karyopharm Therapeutics Inc. [KPTI] to Ring The NASDAQ Stock Market Closing Bell

